Project CBD

FEBRUARY 28, 2023

sativa do not naturally contain cannabinoids, but they can become contaminated with CBD from other plant parts during processing. 13 Although many review authors reported inconclusive findings due to low-quality studies, they noted that evidence from human clinical trials seems to support CBD’s positive effects on nociceptive pain (i.e.,

CBD 144

CBD Seed-To-Sale Food Access 144

CannaMD

MARCH 8, 2021

Download CannaMD ‘s official opposition memo , outlining court precedents, research highlights, and more details regarding the Federal Communications Commission and U.S. Authorizing the department to sample marijuana delivery devices from a dispensing facility to determine safety [p. 1, line 14]. 1, line 17]. 1, line 19].

THC 116

THC Research and Development Treatment Patients 116

TheAnswerPage

JANUARY 11, 2022

We also provide free downloadable resources: ‘The Endocannabinoid System and Medical Marijuana in 15 minutes!’ and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JUNE 10, 2021

The Traffic Safety Culture Index is an annual survey with national scope and multiple measures relevant to driving after marijuana use. Because THC presence is an imperfect proxy for impairment [ 10 ], driving data may be limited in clarifying what traffic safety risks, if any, are associated with permissive marijuana policies.

Policy 59

Policy Safety Marijuana Data 59

Cannabis Law Report

NOVEMBER 24, 2019

Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. the person’s clinical condition is stable. plant-derived cannabinoids such as pure cannabidiol (CBD). There is limited evidence on the safety of cannabis-based medicinal products during pregnancy and breastfeeding.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Framings that more often carried a negative tone were related to poor evidence and safety issues. 2016 ; Sznitman et al.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Peter’s podcast has tens of millions of downloads, with many episodes discussing psychedelics and mental health. Rick Doblin, Ph.D,

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51